Newamsterdam Pharma Company Nv (NAMS)

Überblick Nachrichten Preisverlauf Financials Warum fällt NAMS? Forum Prognose

Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	90.80% 0.032	0.348	19.14	2.978	12.77
Operating Expenses	18.96% 66.01	55.49	54.78	71.90	56.00
Benefits Costs and Expenses	3.60% 74.95	72.35	36.51	42.51	104.95
Costs And Expenses	3.60% 74.95	72.35	36.51	42.51	104.95
Depreciation and Amortization	6.40% 0.133	0.125	0.107	0.113	-
Operating Income/Loss	19.65% -65.98	-55.14	-35.63	-68.92	-43.23
Income/Loss From Continuing Operations Before Tax	4.05% -74.92	-72.00	-17.36	-39.53	-92.18
Income/Loss From Continuing Operations After Tax	4.05% -74.92	-72.00	-17.36	-39.53	-92.18
Net Income/Loss	4.05% -74.92	-72.00	-17.36	-39.53	-92.18
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	99.56% 0.5198	119.00	118.56	116.12	1.6912
Diluted Average Shares	99.56% 0.5198	119.00	118.56	116.12	1.6912
Basic Earnings Per Share	3.28% -0.63	-0.61	-0.15	-0.34	-0.95
Diluted Earnings Per Share	3.28% -0.63	-0.61	-0.15	-0.34	-0.95
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-